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Purpose: Urokinase-type plasminogen activator (uPA) is a protease involved in tissue remodeling and cell migration.
Little is known about the expression of uPA in pterygium. The purpose of this study was to investigate the expression of
uPA mRNA and activities in various stages of surgically excised pterygia specimens and cultured pterygium fibroblasts
and to compare them with normal conjunctival tissues and fibroblasts.
Methods: The expression of uPA mRNA and activity in 15 pterygium tissues and cultured fibroblasts from pterygium
were  measured  using  quantitative  RT–PCR  and  zymography.  Five  normal  conjunctiva  specimens  and  cultured
conjunctival fibroblasts were tested as the controls.
Results: The expression of uPA mRNA and activities in pterygia and pterygium fibroblasts were significantly greater
than those of the normal samples (p<0.05) and were closely related to the progression of pterygium. The amounts of
uPA mRNA and activities in early, moderate, and advanced pterygia were 100%, 208%, and 311% and 100%, 157%, and
280% of the early stage specimens, respectively. The amounts of uPA mRNA and the activities in cultured pterygium
fibroblasts isolated from early, moderate, and advanced pterygium specimens were 100%, 219%, and 457% and 100%,
198% and 355% of early stage fibroblasts, respectively.
Conclusions: Overexpression of uPA was present in pterygium and their fibroblasts. The expression of uPA by pterygium
increased  significantly  following  the  progression  of  the  pterygium.  The  increased  expression  of  uPA  may  covert
plasminogen to plasmin, degrade extracellular matrixes, stimulate cell migration, induce angiogenesis, and plays an
important role in the development and progression of pterygium.
Pterygium  is  a  sun  radiation-related  common  ocular
surface disease that can obscure vision. It is a wing-shaped,
epithelial-covered,  highly  proliferative  and  invasive
fibrovascular lesion that originates from the limbus [1-16].
Compared  with  normal  fibroblasts,  pterygium  fibroblasts
grow much faster in a medium containing a low concentration
of serum and can grow in a semisolid agar, indicating that
these cells represent tumor-like transformed cells [17].
Urokinase-type plasminogen activator (uPA) is a serine
protease  that  coverts  plasminogen  to  plasmin  and  then
activates pro-matrix metalloproteinases (MMPs) into MMPs;
degrades various extracellular matrixes (ECM); stimulates
cell  migration,  proliferation  and  chemotaxis;  inhibits
apoptosis; and induces angiogenesis. uPA plays an important
role in tissue remolding; angiogenesis; and the progression,
invasion, and metastasis of tumors [18-25].
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The  expression  of  uPA  in  pterygium  fibroblasts  and
tissues has not been studied extensively [8,9]. Very little is
known  about  the  expression  and  secretion  of  uPA  in
pterygium cells and tissues and on the role of uPA in the
pathogenesis of pterygium. To the best of our knowledge, no
researchers have reported the relationship between the uPA
expression and the extent/stages of pterygia.
The present study investigated uPA mRNA and activity
levels in pterygium tissues collected from 15 patients who had
pterygium removed and cultured fibroblasts isolated from 15
pterygia specimens. Five normal conjunctiva specimens and
fibroblasts  were  tested  as  the  controls.  We  studied  the
relationship between the expression of uPA in pterygia tissues
and the stages of pterygium. The expression of uPA in cultured
fibroblasts isolated from pterygia at different stages was also
studied and compared with fibroblasts isolated from normal
conjunctiva.
METHODS
Subjects: All specimens were obtained from patients after
surgery with the patients’ informed consent, in accordance
with the tenants of the Helsinki Declaration. The present study
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23was reviewed and approved by the Institutional Review Board
of Show Chwan Memorial Hospital on Feb. 15, 2007 (code:
960102).
The external eye of each patient was photographed before
the operation. Pterygia were classified into three stages by the
surgeon, based on the extent of the pterygium (Figure 1):
Stage  1:  The  head  of  pterygia  did  not  reach  the
midline between the limbus and pupillary margin.
Stage 2: The head of pterygia passed the midline but
did not reach the pupil.
Stage 3: The head of pterygia passed the pupillary
margin.
Pterygium specimens were collected from 15 pterygium
patients  (7  males  and  8  females,  aged  62.08±12.01  years
[mean±SD]). All of these pterygia were progressive in nature.
The  ages  of  the  patients  in  stages  I,  II,  and  III  were
63.75±10.21  (mean±SD),  60.4±13.15,  and  62.50±15.29
years,  respectively.  The  gender  distribution  (male/female)
was  2/3,  3/2,  and  2/3  in  stage  I,  II,  and  III  patients,
respectively. Normal conjunctival tissues were obtained from
5 individuals (3 females and 2 males) aged 63.67±7.02 years
(mean±SD).
Excised tissues were divided laterally into two identical
and symmetric pieces. One piece (for measurement of tissue
uPA mRNA and activity) was frozen and stored at −70 °C until
processing.  Another  piece  was  used  for  the  isolation  and
cultivation of pterygium fibroblasts.
Isolation and cultivation of pterygium fibroblasts: Fibroblasts
were  obtained  from  15  pterygia  specimens  and  5  normal
conjunctival specimens (one cell line from each specimen) by
using  the  explants  methods  reported  by  Li  et  al.  [8]  and
practiced by us previously [16]. Briefly, the head of pterygium
specimen or normal conjunctiva was cut into small pieces,
washed, and placed into a culture dish. Dulbecco’s Modified
Eagle’s  Medium  (DMEM)  with  15%  fetal  bovine  serum
(FBS)  was  added  to  cover  the  explants  (all  from  Gibco,
Carlsbad, CA). The culture dish was put in a CO2-regulated
incubator. The culture medium was replaced 3 times a week
after  the  appearance  of  the  outgrowth  of  cells  from  the
explants.  After  the  primary  cultures  became  confluent,
cultured fibroblasts were detached from the dish with a 0.05%
trypsin/0.01%  EDTA  solution  (Gibco,  Carlsbad,  CA)  and
passaged for subculture with a 1:3 split. In some cultures,
epithelial cells also migrated from the explants in the early
stage. However, epithelial cells rapidly became terminally
differentiated and lost their viability in a medium with high
Figure 1. Schematic picture shows the
different stages of pterygia. Stage 1: The
head  of  pterygia  did  not  reach  the
midline  between  the  limbus  and
pupillary margin. Stage 2: The head of
pterygia passed the midline but did not
reach the pupil. Stage 3: The head of
pterygia passed the pupillary margin.
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24levels of serum and Ca2+. Furthermore, during subculturing,
the fibroblasts detached from the well much easier than the
epithelial cells. After the detachment of the fibroblasts was
nearly completed, serum was added to stop the effect of the
enzyme so that the epithelial cells remained in the well and
could  not  be  passed  onto  the  subculture.  Therefore,  only
fibroblasts were present in the subcultures.
An  immunocytochemical  study  was  performed  to
identify  the  cell  types.  The  epithelial  cells  contained
cytokeratin antigens, but the fibroblasts did not [26].
For the uPA experiment, the fibroblasts in the second or
third subcultures were seeded into a 35-mm dish and cultured
with DMEM with 10% FBS. The culture was washed with
PBS after near confluence and cultured with DMEM without
FBS for 48 h. The conditioned medium was collected and
centrifuged.  The  supernatant  was  stored  at  −70  °C  until
zymography analysis was conducted on the uPA activity. The
fibroblasts were trypsinized and stored at −70 °C until uPA
mRNA of was measured. Fifteen fibroblast cell lines from 15
pterygium specimens and 5 fibroblast cell lines from 5 normal
conjunctival tissues were tested.
Determination of uPA by casein zymography: Pterygium or
normal conjunctival specimens were rinsed with PBS twice
and scraped with 0.3 ml of a cold cell lysis buffer containing
protease inhibitors cocktail. The protein concentrations of
total lysates were determined by the Bradford assay [27].
The activities of uPA in the conditioned culture medium
and pterygium tissue were measured by casein zymography
protease assays, as previously described by us (Yang et al.
[28]). Briefly, the cultured media or lysates of pterygium
tissues were prepared with an SDS sample buffer without
boiling or reduction and then subjected to 2% casein and
20 μg/ml plasminogen in 8% SDS–PAGE electrophoresis.
After electrophoresis, the gels were washed with 2.5% Triton
X-100 and then incubated in a reaction buffer (40 mM Tris-
HCl, pH 8.0; 10 mM CaCl2 and 0.01% NaN3) at 37 °C for 12
h. Then the gels were stained with Comassie brilliant blue
R-250 (all from Sigma, St. Louis, MO). The uPA standard
from ELISA kits by American Diagnostica was used as the
positive control and buffer was loaded as the negative control.
β-actin was used as an internal loading control and analysis
by western blotting. The relative photographic densities of
uPA were quantitied by scanning the photographic negatives
on a gel documentation and analysis system (AlphaImager
2000; Alpha Innotech Corporation, San Leandro, CA).
RNA preparation and quantitative real-time PCR: Total RNA
was isolated from tissue specimens and cultured fibroblast
cells  using  Trizol  (Life  Technologies,  Grand  Island,  NY)
according  to  the  manufacturer’s  instructions.  For  reverse
transcription,  first-strand  cDNA  synthesis  was  performed
with random primers (hexamers; Promega, Madison, WI) and
100 U of moloney murine leukemia virus reverse transcriptase
(Promega) and performed at 42 °C for 60 min and terminated
at 90 °C for 10 min. The quantitative real-time PCR analysis
was  performed  using  Taqman  one-step  PCR  Master  Mix
(Applied Biosystems, Carlsbad, CA). A total of 100 ng cDNA
was added per 25 μl reaction with uPA primers and Taqman
probes. The u-PA (Hs01547054_m1) and glyceraldehyde 3-
phosphate  dehydrogenase  (GAPDH;  Hs99999905_m1)
primers and probe were designed using commercial software
(ABI  PRISM  Sequence  Detection  System;  Applied
Biosystems [29]). Quantitative real-time PCR assays were
performed in triplicate on a StepOnePlus sequence detection
system (Applied Biosystems). The cycling conditions were 10
min of polymerase activation at 95 °C followed by 40 cycles
at 95 °C for 15 s and 60 °C for 60 s. The threshold was set
above the nontemplate control background and within the
linear phase of the target gene amplification to calculate the
cycle number at which the transcript was detected.
Statistical  analysis: Statistical  significances  of  differences
throughout this study were calculated by an ANOVA one-way
test in comparing data from more than two groups and using
a Student’s t-test for comparing data between two groups. The
data was analyzed using SPSS statistical software (SPSS Inc.,
Chicago,  IL).  A  difference  at  p<0.05  was  considered
statistically significant.
RESULTS
uPA activities in pterygium and normal conjunctival tissues:
uPA activities in 5 normal conjunctival and 15 pterygia tissues
(5  tissues  from  each  stage)  were  measured  by  casein
zymography. uPA activities in pterygium were 2.78 fold of
the normal conjunctival tissues, and the difference of uPA
activities  between  pterygium  and  normal  tissues  was
statistically  significantly  (p<0.05;  Figure  2A,B).  uPA
activities  (expressed  as  percentages  of  stage  I  pterygium
specimens) in stages I, II, and III pterygium tissues were
100%, 208%, and 311%, respectively. Pterygium tissues at
stage III had significantly higher uPA levels than that at stages
I and II (Figure 2A,C, p<0.05), the difference between stage
I and stage II was also statistically significant (Figure 2A,C,
p<0.05).
uPA  mRNA  levels  in  pterygium  and  normal  conjunctival
tissues:  uPA  mRNA  levels  in  pterygium  tissues  were
measured by quantitative real-time PCR assay. Data from
Figure 2 shows that uPA mRNA levels were significantly
greater than those of normal conjunctival tissues. uPA mRNA
levels in pterygium were 3.25 fold of the normal conjunctival
tissues, and the difference of uPA mRNA levels between
pterygium and normal tissues was statistically significantly
(p<0.05). In pterygium specimens, uPA mRNA levels were
expressed  at  various  stages  (Figure  3).  Amounts  of  uPA
mRNA  (expressed  as  percentages  of  stage  I  pterygium
specimens) in stages I, II, and III pterygium tissues were
100%, 157%, and 280%, respectively. Expression of uPA in
stages III and II specimens was significantly greater than that
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25of stage I specimens, the differences in uPA mRNA levels
between  stage  II  and  III  tissues  was  also  statistically
significant (p<0.05, Figure 3).
uPA activities in conditioned media from cultured pterygium
and normal conjunctival fibroblasts: uPA activity levels in
conditioned media from cultured pterygium fibroblasts were
3.30 fold of the cultured normal conjunctival fibroblasts. The
difference of uPA activities between pterygium and normal
conjunctival  fibroblasts  was  statistically  significantly
(p<0.05; Figure 4A,B). uPA activities in conditioned media
from stages I, II, and III pterygium fibroblasts (expressed as
percentages  of  stage  I  pterygium  fibroblasts)  were  100%,
219%, and 457%, respectively (Figure 4A,C). uPA activities
in conditioned medium from stage III pterygium fibroblasts
were significantly greater (p<0.05) than those in the media
from stages I and II pterygium fibroblasts (Figure 4C). uPA
levels  in  conditioned  medium  from  stage  II  pterygium
fibroblasts was also significantly greater than those from stage
I pterygium fibroblasts (p<0.05, Figure 4C).
uPA  mRNA  levels  in  cultured  pterygium  and  normal
conjunctival  fibroblasts:  uPA  mRNA  levels  in  cultured
pterygium fibroblasts were 2.91 old of the cultured normal
conjunctival fibroblasts. The difference of uPA mRNA levels
between  cultured  pterygium  fibroblasts  and  normal
conjunctival  fibroblasts  were  statistically  significantly
(p<0.05). uPA mRNA levels (expressed as percentages of
stage I pterygium fibroblasts) in stages I, II, and III pterygium
fibroblasts were 100%, 198%, and 355%, respectively (Figure
5). The difference in uPA mRNA levels was significant in
fibroblasts between stage I and stage II (p<0.05) and between
stage II and stage III (Figure 5; p<0.05).
DISCUSSION
Urokinase-type  plasminogen  activator  (uPA)  is  a  serine
protease  that  coverts  plasminogen  to  plasmin.  It  can  be
produced by various cells, especially tumor cells or stromal
cells  (e.g.,  fibroblasts)  adjacent  to  a  tumor  [19-21,23,24,
30-36]. uPA is produced as a 53 kDa single-chain protease,
which is inactive and can be converted into an active two-
chain uPA upon binding to the cell surface uPA receptor
(uPAR) and cleavage by plasmin [18-20,22-24].
Activated uPA converts plasminogen to plasmin, a serine
proteinase, which is capable of degrading fibrin. Furthermore,
plasmin  also  degrades  basement  membrane  and  a  broad
Figure  2.  uPA  activities  in  normal
conjunctival  and  pterygium  tissues  at
various  stages  measured  by  casein
zymography.  A:  uPA  activity  was
analysis by casein zymography. The u-
PA  standard  from  ELISA  kits  by
American Diagnostica was used as the
positive  control  (PC)  and  buffer  was
loaded  alone  as  the  negative  control
(NC). β-actin was used as an internal
loading control and analysis by western
blotting. B: Comparison of uPA activity
levels between normal conjunctival and
pterygium  tissues.  Data  are  given  as
mean±SD  *Significant  difference
(p<0.05)  between  normal  conjunctiva
and  pterygium.  C:  Levels  of  uPA  in
pterygium tissues at various stages. Data
are  given  as  mean±SD  *Significant
difference  (p<0.05)  compared  with
stage I. #Significant difference (p<0.05)
compared with stage II.
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26spectrum  of  ECM,  including  fibronectin,  vitronectin,  and
laminin,  leading  to  tumor  cell  invasion  and  metastasis
[19-24,37,38]. Plasmin also activates pro-matrix MMP into
MMP, including MMPs-1, −2, −3, −9, −10, and 13, and results
in further degradation of various ECM [22-24]. Upregulation
of MMPs can be induced by binding of uPA with uPAR
[21]. Many growth factors, including basic fibroblast growth
factor (bFGF), vascular endothelial growth factor (VEGF),
hepatocytes growth factor (HGF), insulin-like growth factor
I (IGF-I), epithelial growth factor (EGF), and transforming
growth factor- β (TGF- β), are activated or released from ECM
by plasmin or MMP [20-24].
The binding of uPA with its receptor uPAR can activate
downstream signaling molecules, including the Ras/ERK and
PI3K/Akt pathways and various transcription factors, which,
in turn, lead to cell proliferation, migration, and invasion
[21,38,39].
uPA plays an important role in various physiologic and
pathological  processes,  including  wound  healing,  tissue
remolding and regeneration, angiogenesis, inflammation, and
tumor progression, especially in the malignant tumor invasion
and  metastasis  [19,23,24].  Various  experimental  model
systems have provided evidence for a causal role of uPA in
cancer invasion and metastasis [19,20,24]. Numerous clinical
and laboratory studies found that the uPA content in various
tumor specimens is significantly increased compared with the
normal tissue [18-24]. uPA is produced and released by the
tumor cells or by stromal cells adjacent to a tumor [19-21,
23,24,30-36]. High uPA levels in primary malignant tumor
specimens correlate with a high incidence of relapse, poor
prognosis, and high mortality in various tumors, including
esophageal, gastric, head and neck, thyroid, breast, colorectal,
liver, pancreatic, prostate, endometrial, kidney, and small cell
lung  cancers;  chondrosarcoma,  glioma,  and  leukemia
[18-24,38].  uPA  was  the  first  proteinase  shown  to  be  a
prognostic marker in human malignancies and it has remains
an important prognostic marker for various human cancers
[18-24,38].
Pterygium  is  a  fibrovascular  tissue  from  the  bulbar
conjunctiva and extends onto the cornea. The progression of
pterygium  is  characterized  by  the  degradation  of  corneal
basement  membrane  and  ECM,  the  development  of
angiogenesis and proliferation of fibrovascular tissue. It has
been reported that the expression of several types of MMPs
(MMP-1, 2, 3, 7, and 9) increases in pterygium and related
cell types (fibroblasts and epithelial cells) [7-16].
Recently,  we  demonstrated  that  MMP-2  and  −9  are
overexpressed in pterygium tissue and fibroblasts isolated
from pterygium. The levels of these MMPs in pterygium and
its  fibroblasts  are  closely  related  to  the  progression  of
pterygium  [16].  Increased  MMPs  dissolve  the  Bowman’s
layer, cause angiogenesis and invasion of pterygium onto the
cornea.
MMPs  are  secreted  in  a  latent  precursor  and  can  be
activated by plasmin [22-24]. uPA is the most important serine
proteinase  that  activates  plasminogen  into  plasmin  and  is
responsible for the tissue degradation and tumor cell invasion
[18-24].  uPA  plays  a  central  role  in  the  mediation  of
Figure  3.  uPA  mRNA  in  normal
conjunctiva  and  pterygium  tissue  at
various stages measured by quantitative
real-time  PCR.  Comparison  of  uPA
mRNA  levels  between  normal
conjunctiva  and  pterygium  tissues  at
various stages. Data are given as mean
±SD  (n=5).  *Significant  difference
(p<0.05)  compared  with  normal.
#Significant  difference  (p<0.05)
compared  with  stage  I.  &Significant
difference  (p<0.05)  compared  with
stage II.
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27pericellular proteolytic activity [38]. However, little is known
about the expression of uPA in pterygium.
Two papers mentioned uPA expression in pterygium as
a part of their studies on the relationship between various
cytokines, growth factors, MMPs with uPA and pterygium.
The results were conflicting [8,9]. One paper reported the
effects of several growth factors on the expression of uPA
protein  and  various  MMPs  in  pterygium  and  normal
conjunctival  fibroblasts.  uPA  released  from  untreated
pterygium  fibroblasts  (approximately  0.37  pg/μg  protein)
seems greater than that from normal conjunctival fibroblasts
(approximately  0.25  pg/μg  protein),  though  no  statistical
analysis was performed by the authors [9]. Another paper
measured the expression of uPA mRNA in pterygium by using
northern  blotting  and  stated  that  expression  of  uPA  in
pterygium  did  not  differ  from  normal  fibroblasts  [8].
However, no statistical treatment was performed to support
this conclusion. The most important parameter of various uPA
levels, uPA activity that determines the ability for activated
plasmin  from  plasminogen,  has  never  been  studied  in
pterygium or its cellular component, and no researchers have
reported the relationship between the uPA level and the extent/
stage of pterygia.
In the present study, overexpression of uPA mRNA and
activities was present in pterygia and pterygium fibroblasts.
The expression of uPA by pterygium and its fibroblasts is
significantly increased with the progression of pterygium. The
occurrence  of  pterygium  shows  similarities  with
tumorigenesis. During tumor development, uPA is one of the
important  factors  involved  in  the  growth,  invasion,  and
metastasis [18-21,24,38]. The expression of uPA in tumor
cells  and  stromal  cells  begins  at  the  earlier  stage  and
progressively increases during the development of tumors
[18-21,24,38]. It has been hypothesized that the pterygium
cells are tumorlike altered limbal fibroblasts and epithelial
cells  [7,17].  Pterygium  fibroblasts  grow  well  in  a  culture
medium with only a low concentration of serum, and they can
grow  in  a  semisolid  sugar,  indicative  of  anchorage-
independent growth, which is a phenotype of transformed or
tumor  cells  [17].  The  present  study  demonstrated  that
fibroblasts from pterygium produce and release higher levels
of uPA compared with normal conjunctival fibroblasts. Cells
from advanced stages of pterygia produce and release more
Figure  4.  uPA  activities  in  the
conditioned media of cultured normal
conjunctival and pterygium fibroblasts
of various stages measured by casein
zymography. Fibroblast cell lines were
isolated  from  pterygia  specimens  at
various  stages.  Normal  fibroblast  cell
lines  were  isolated  from  normal
conjunctival  specimens.  Cells  were
cultured in serum-free culture medium
for 48 h. The conditioned medium was
collected, and the activity of uPA was
measured by casein zymography. The u-
PA  standard  from  ELISA  kits  by
American Diagnostica was used as the
positive  control  (PC)  and  buffer  was
loaded  alone  as  the  negative  control
(NC). A: uPA activity of medium from
normal and pterygium fibroblasts was
analyzed  by  casein  zymography.  B:
Comparison of levels of uPA activity in
conditioned  media  from  normal  and
pterygium fibroblasts. Data are given as
mean±SD  *Significant  difference
(p<0.05)  between  the  normal  and
pterygium fibroblasts. C: Levels of uPA
activity  in  conditioned  media  of
fibroblasts  from  various  stages  of
pterygium. Data are given as mean±SD
*Significant  difference  (p<0.05)
compared  with  stage  I.  #Significant
difference  (p<0.05)  compared  with
stage II.
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28uPA  than  the  early-stage  pterygium  fibroblasts.  This  is
consistent with the findings that fibroblasts adjacent to the
tumor overexpress uPA and play a role in the tumor invasion
and progression [19-21,24,30-36].
Understanding of the role of uPA in the development of
pterygium  has  relevance  to  devising  a  new  strategy  of
pterygium treatment [24,37-40]. The involvement of the uPA
system  in  cancer  progression  and  the  observation  that  its
inhibition  is  devoid  of  toxicity,  as  demonstrated  in  uPA-
deficient mice, identifies the uPA system as a suitable target
for  anti-cancer  therapies  [24,37-40].  Several  therapeutic
strategies inhibiting the inhibition of the uPA system have
been or are being developed for suppression of tumor growth
and  progression,  including  anti-uPA  antibodies,  small
molecular uPA inhibitors, cytotoxins targeting uPA/uPAR
components,  antisense  therapy,  and  RNA  interference
technology [24,37-40]. Various selective uPA inhibitors have
shown promising results in experimental animal studies and
preclinical testing [24,37-40]. Some of these therapies have
been proven to be safe and well tolerated in Phase I clinical
studies  and  have  entered  Phase  II  clinical  studies  [24].
Therefore, further studies in this field might be helpful for the
development  of  novel  therapies  in  the  management  of
pterygium and in the prevention of its relapse.
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